Naseem Zojwalla
Directeur Technique/Scientifique/R&D chez OLEMA PHARMACEUTICALS, INC.
Fortune : 971 896 $ au 30/06/2024
Profil
Naseem Zojwalla currently works at Peloton Therapeutics, Inc., as Head-Clinical Development & Strategy, Turning Point Therapeutics, Inc., as Vice President-Clinical Development, Columbia University Medical Center, as Assistant Clinical Professor-Medicine, and Olema Pharmaceuticals, Inc., as Chief Medical Officer from 2022.
Dr. Zojwalla received her undergraduate degree from Stanford University and doctorate degree from Temple University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/05/2024 | 89 824 ( 0,16% ) | 971 896 $ | 30/06/2024 |
Postes actifs de Naseem Zojwalla
| Sociétés | Poste | Début |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 31/01/2022 |
| TURG POIN | Directeur Technique/Scientifique/R&D | - |
| PELOTON THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
| Columbia University Medical Center | Corporate Officer/Principal | - |
Formation de Naseem Zojwalla
| Temple University School of Medicine | Doctorate Degree |
| Stanford University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
